Your browser doesn't support javascript.
loading
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Lemech, Charlotte; Woodward, Natasha; Chan, Nancy; Mortimer, Joanne; Naumovski, Louie; Nuthalapati, Silpa; Tong, Bo; Jiang, Fang; Ansell, Peter; Ratajczak, Christine K; Sachdev, Jasgit.
Afiliación
  • Lemech C; Scientia Clinical Research, Sydney, NSW, Australia.
  • Woodward N; Mater Misericordiae Ltd and Mater Research Institute/University of Queensland, Raymond Terrace, South Brisbane, QLD, Australia.
  • Chan N; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Mortimer J; City of Hope National Medical Center, Duarte, CA, USA.
  • Naumovski L; AbbVie Inc, North Chicago, IL, USA.
  • Nuthalapati S; AbbVie Inc, North Chicago, IL, USA.
  • Tong B; AbbVie Inc, North Chicago, IL, USA.
  • Jiang F; AbbVie Inc, North Chicago, IL, USA.
  • Ansell P; AbbVie Inc, North Chicago, IL, USA.
  • Ratajczak CK; AbbVie Inc, North Chicago, IL, USA.
  • Sachdev J; HonorHealth Research Institute, Scottsdale, AZ, 85258, USA. jsachdev@honorhealth.com.
Invest New Drugs ; 38(6): 1815-1825, 2020 12.
Article en En | MEDLINE | ID: mdl-32524319
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptores de Prolactina / Inmunoconjugados / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2020 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptores de Prolactina / Inmunoconjugados / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2020 Tipo del documento: Article País de afiliación: Australia